Clinical Trials

643 enrolled 17 charts 1 FDA

Phase 1/2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01116648 2026-03-05

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

155 enrolled 34 charts

BreastGynecologic

Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms

NCT02345265 2026-03-05

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

70 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

579 enrolled 17 charts

Phase 2/3 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02502266 2026-03-05

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

582 enrolled 21 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04697628 2026-02-24

innovaTV 301

502 enrolled 18 charts 1 FDA

Uterine Cervical Neoplasms

NCT03617679 2026-02-23

Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

79 enrolled 12 charts

Endometrial Neoplasms

NCT04221945 2026-02-20

KEYNOTE-A18

1,060 enrolled 30 charts 1 FDA

Phase 1/2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT03734692 2026-02-12

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

24 enrolled 59 charts

Ovarian Cancer Recurrent

NCT01081951 2026-02-05

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

162 enrolled 15 charts

Ovarian Neoplasms

NCT03763838 2026-02-05

Acupressure for Fatigue in Ovarian Cancer Survivors

Phase NA Completed

171 enrolled 14 charts

Phase 1 Active not recruiting

Fatigue, Ovarian Neoplasms

NCT03120624 2026-02-04

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

34 enrolled 16 charts

Endometrial Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

617 enrolled 29 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT03884101 2026-02-02

LEAP-001

842 enrolled 25 charts

Endometrial Neoplasms

NCT02405221 2026-01-29

Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer

Phase 1 Completed

15 enrolled 16 charts

Phase 1/2 Active not recruiting

Uterine Cervical Neoplasms

NCT02734004 2026-01-29

MEDIOLA

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT03984695 2026-01-28

SHE-WOMEN

Phase NA Active not recruiting

279 enrolled 17 charts

BreastGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Contraception Behavior, Sexually Transmitted Diseases

NCT05041257 2026-01-09

PICCOLO

Phase 2 Completed

79 enrolled 14 charts

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT05082025 2026-01-09

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

Phase 2 Terminated

7 enrolled 10 charts

Ovarian Neoplasms, Endometrial Neoplasms

NCT02948426 2026-01-08

Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Phase 1 Terminated

18 enrolled 19 charts

Carcinoma, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01048853 2026-01-07

Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer

Phase NA Terminated

137 enrolled 15 charts

Cervical Adenocarcinoma

NCT03671811 2026-01-06

Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy

44 enrolled 12 charts

BreastGynecologicHead & NeckThoracic

Endometrial Hyperplasia, Endometrial Neoplasms

NCT05524454 2026-01-06

CONFIGURE

Phase NA Completed

41 enrolled 6 charts

Breast Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Pelvic Neoplasms

NCT00980954 2025-12-31

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

236 enrolled 28 charts

Uterine Cervical Neoplasms

NCT03602859 2025-12-31

FIRST

1,400 enrolled 18 charts

Ovarian Neoplasms

NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

1,052 enrolled 27 charts

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT04269200 2025-12-23

DUO-E

805 enrolled 18 charts 1 FDA

Endometrial Neoplasms

NCT05483933 2025-12-23

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Phase 1 Completed

86 enrolled 17 charts

Phase 1 Active not recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04670068 2025-12-22

Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian

4 enrolled 8 charts

Phase 1 Active not recruiting

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT05276973 2025-12-19

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

25 enrolled 14 charts

BreastGastrointestinalGynecologicHead & NeckThoracic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05001347 2025-12-16

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

Phase 2 Completed

25 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03422198 2025-12-12

SAVE

Phase 3 Recruiting

188 enrolled 15 charts

GynecologicSarcoma

Endometrial Clear Cell Adenocarcinoma

NCT04339140 2025-12-11

Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer

Phase 2 Completed

5 enrolled 4 charts

Phase NA Active not recruiting

Ovarian Neoplasms

NCT04905082 2025-12-11

HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics

465 enrolled 11 charts

BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT01844986 2025-12-10

SOLO-1

450 enrolled 18 charts 1 FDA

Pathologic Complete Response, Ovarian Neoplasms

NCT06964165 2025-11-26

A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)

Phase 2 Terminated

36 enrolled 11 charts

Ovarian Neoplasms

NCT01081262 2025-11-25

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

50 enrolled 13 charts